According to filings with the U.S. Securities and Exchange Commission, Noveome Biotherapeutics is raising $40,190,480.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Patrick Welch played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Noveome Biotherapeutics
Noveome Biotherapeutics, Inc. is a clinical stage company focused on breakthrough therapies for the regenerative repair of inflamed or damaged tissues. The company, originally founded as Stemnion, Inc., is located in the heart of Pittsburgh near the Southside Works. Noveome is passionate about growing its business in Allegheny County and helping the region to become a world leader in biotherapeutic research and development. Noveome Biotherapeutics, Inc. is a dynamic biopharmaceutical company with an innovative platform technology that represents a paradigm shift in drug development. Unlike most drugs that are single molecules directed at specific indications, Noveomes product is a complex mixture of biomolecules that is believed to have the ability to treat a wide range of conditions and injuries. Noveome collaborates with major research centers to advance these therapeutic applications.

To learn more about Noveome Biotherapeutics, visit http://www.noveome.com/

Contact:
Patrick Welch, Chief Executive Officer
412-402-9914

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.